Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
147
datasets available to search
ShareScore release 0.7.1
Dataset results
147 results for “PCSK9”
GWAS Summary Statistics from "Sex and statin-related genetic associations at the PCSK9 gene locus – results of genome-wide association meta-analysis"
<p>GWAMA summary statistics of PCSK9 levels stratified by sex and statin useage in Europeans.</p> <p>When using this data, please cite:</p> <p>Pott, J., Kheirkhah, A., Gadin, J.R. <em>et al.</em> Sex and statin-related genetic associations at the <em>PCSK9</em> gene locus: results of genome-wide association meta-analysis. <em>Biol Sex Differ</em> <strong>15</strong>, 26 (2024). https://doi.org/10.1186/s13293-024-00602-6</p> <p>All txt files contain the following columns:</p> <ul> <li>markername (unique SNP ID)</li> <li>chr</li> <li>bp_hg19 (base position according to hg19)</li> <li>EA (effect allele)</li> <li>OA (other allele)</li> <li>EAF (effect allele frequency)</li> <li>info (minimal info score across all used studies)</li> <li>nSamples (sample size per SNP)</li> <li>nStudies (in case of double-stratified data: number of studies; in case of single-stratified data: 2, as it is a meta-analysis of the two double-stratified data sets)</li> <li>beta (effect estimate)</li> <li>SE (standard error)</li> <li>pval (p-value)</li> <li>I2 (SNP heterogeneity across studies)</li> <li>invalidAssoc (TRUE/FALSE flag if this variant was excluded in our analysis)</li> <li>reason4exclusion (reason why this SNP was excluded)</li> <li>phenotype (phenotyp setting)</li> </ul>
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy reduces the level of DNA damage in patients with heterozygous familial hypercholesterolemia
<p><span><span>Heterozygous Familial Hypercholesterolaemia (HeFH) is a common autosomal dominant genetic disease (1:300) characterized by elevated LDL-C leading to premature atherosclerosis. Treatment with a PCSK9 inhibitor (iPCSK9) is recommended in high cardiovascular risk FH patients if the treatment goal is not achieved on maximal tolerated statin plus ezetimibe. </span></span><span>The aim of this study was to </span><span><span>examine the changes in DNA damage in HeFH patients associated with iPCSK9 use. </span></span><span>Fifty-seven patients were included: a normolipidemic group (control; n=20) and patients with HeFH (study group; n=36). DNA damage was determined by alkaline comet assay. PCSK9 protein level was assessed by ELISA. </span><span>The levels of Lp(a) in human serum were quantitatively turbidimetrically assay.</span><span> </span><span>PCSK9i treatment was associated with lower DNA damage, Lp(a), PCSK9 and lipid profile than before treatment. However, 20 of 36 patients still had Lp(a) values above 125 nmol/L, and reduced Lp(a) did not correlate with reduced DNA damage. Reduced PCSK9 moderately (r=0.48) correlates with reduced DNA damage</span><span><span>. PCSK9i therapy reduces the level of DNA damage in HeFH patients, regardless of the type of inhibitor. The reduction in DNA damage is not related to the changes in lipid profile or Lp(a) induced by PCSK9i, but it is dependent on PCSK9 level.</span></span></p>
Summary Statistics from "Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2"
<p>GWAMA summary statistics of PCSK9 levels using fixed-effect model. Genome-wide data is given for Europeans with statin adjustment and Europeans without statin treatment only (subset of the population). In addition, locus-wide data of the PCSK9 gene locus for African-Americans without statin treatment is listed.</p> <p>When using this data, please cite: Pott J, Gadin J, Theusch E, et al.. Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2. Hum Mol Genet. 2021 Sep 30:ddab279. doi: 10.1093/hmg/ddab279. PMID: 34590679</p> <p>All txt files contain the following columns:</p> <ul> <li>markername</li> <li>chr</li> <li>bp_hg19 (base position according to hg19)</li> <li>ea (effect allele)</li> <li>oa (other allele)</li> <li>eaf (effect allele frequency)</li> <li>info (minimal info score across all used studies)</li> <li>nSamples (sample size per SNP)</li> <li>nStudies (number of studies)</li> <li>beta (effect estimate)</li> <li>se (standard error)</li> <li>p (p-value)</li> <li>I2 (SNP heterogeneity across studies)</li> <li>phenotype (phenotyp setting)</li> </ul>
Data-driven transcriptomics analysis identifies PCSK9 as a novel key regulator in liver aging. (Histology Images)
<p>These are the histology images on "Data-driven transcriptomics analysis identifies PCSK9 as a novel key regulator in liver aging."</p>
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
ClinicalTrials.gov study NCT01588496. IPD Sharing: Not stated. Countries: 12. Publications: 3.
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
ClinicalTrials.gov study NCT01624142. IPD Sharing: Not stated. Countries: 18. Publications: 6.
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
ClinicalTrials.gov study NCT01763866. IPD Sharing: Not stated. Countries: 21. Publications: 12.
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
ClinicalTrials.gov study NCT01375764. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
ClinicalTrials.gov study NCT01763905. IPD Sharing: Not stated. Countries: 14. Publications: 11.
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
ClinicalTrials.gov study NCT02189837. IPD Sharing: Not stated. Countries: 1. Publications: 4.
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
ClinicalTrials.gov study NCT01380730. IPD Sharing: Not stated. Countries: 5. Publications: 3.
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
ClinicalTrials.gov study NCT02634580. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
ClinicalTrials.gov study NCT01375777. IPD Sharing: Not stated. Countries: 5. Publications: 1.
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
ClinicalTrials.gov study NCT05261126. IPD Sharing: YES. Countries: 8. Publications: 1.
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
ClinicalTrials.gov study NCT01763918. IPD Sharing: Not stated. Countries: 14. Publications: 7.
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
ClinicalTrials.gov study NCT02729025. IPD Sharing: Not stated. Countries: 3. Publications: 4.
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
ClinicalTrials.gov study NCT01813422. IPD Sharing: Not stated. Countries: 32. Publications: 4.
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
ClinicalTrials.gov study NCT01516879. IPD Sharing: Not stated. Countries: 9. Publications: 12.
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholes
ClinicalTrials.gov study NCT06450366. IPD Sharing: YES. Countries: 8. Publications: 0.
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
ClinicalTrials.gov study NCT02867813. IPD Sharing: YES. Countries: 7. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.